ABCG2 p.Lys86Ala
Predicted by SNAP2: | A: D (95%), C: D (95%), D: D (95%), E: D (95%), F: D (95%), G: D (95%), H: D (95%), I: D (95%), L: D (95%), M: D (95%), N: D (95%), P: D (95%), Q: D (95%), R: D (95%), S: D (95%), T: D (95%), V: D (95%), W: D (95%), Y: D (95%), |
Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, L: D, M: D, N: D, P: D, Q: D, R: N, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Identification of residues in ABCG2 affecting prot... Biosci Rep. 2015 Jul 17;35(4). pii: e00241. doi: 10.1042/BSR20150150. Haider AJ, Cox MH, Jones N, Goode AJ, Bridge KS, Wong K, Briggs D, Kerr ID
Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.
Biosci Rep. 2015 Jul 17;35(4). pii: e00241. doi: 10.1042/BSR20150150., [PMID:26294421]
Abstract [show]
ABCG2 is an ABC (ATP-binding cassette) transporter with a physiological role in urate transport in the kidney and is also implicated in multi-drug efflux from a number of organs in the body. The trafficking of the protein and the mechanism by which it recognizes and transports diverse drugs are important areas of research. In the current study, we have made a series of single amino acid mutations in ABCG2 on the basis of sequence analysis. Mutant isoforms were characterized for cell surface expression and function. One mutant (I573A) showed disrupted glycosylation and reduced trafficking kinetics. In contrast with many ABC transporter folding mutations which appear to be 'rescued' by chemical chaperones or low temperature incubation, the I573A mutation was not enriched at the cell surface by either treatment, with the majority of the protein being retained in the endoplasmic reticulum (ER). Two other mutations (P485A and M549A) showed distinct effects on transport of ABCG2 substrates reinforcing the role of TM helix 3 in drug recognition and transport and indicating the presence of intracellular coupling regions in ABCG2.
Comments [show]
None has been submitted yet.
No. Sentence Comment
110 A further three control mutations were analysed, namely a substitution of lysine to alanine in the Walker-A motif (K86A), a substitution of glutamate to glutamine in the Walker-B motif (E211Q) and a substitution of asparagine to glutamine at the site of glycosylation (N596Q).
X
ABCG2 p.Lys86Ala 26294421:110:115
status: NEW155 These two mutants behaved in this assay in essentially the same way as the K86A and E211Q catalytically inactive mutants (result not shown).
X
ABCG2 p.Lys86Ala 26294421:155:75
status: NEW172 sfGFP-M549A and the catalytically inactive sfGFP-K86A isoform showed no Ko143-inhibited MX transport.
X
ABCG2 p.Lys86Ala 26294421:172:49
status: NEW173 With PhA, neither sfGFP-K86A nor sfGFP-M549A showed Ko143-inhibitable transport.
X
ABCG2 p.Lys86Ala 26294421:173:24
status: NEW